HighTower Advisors
BIB icon

HighTower Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

HighTower Advisors’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,108
Closed -$484K – 1584
2015
Q1 		$484K Sell
6,108
-100
-2% -$7.42K 0.01% 1086
2014
Q4 		$390K Hold
6,208
– – 0.01% 1135
2014
Q3 		$323K Sell
6,208
-5,600
-47% -$271K 0.01% 1177
2014
Q2 		$548K Hold
11,808
– – 0.01% 1023
2014
Q1 		$471K Buy
+11,808
New +$536K 0.01% 998

Other funds holding BIB

AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HighTower Advisors's BIB Position: Q2 2015 in Review

HighTower Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2015, closing a stake of 6,108 shares — an estimated $484K sold.

HighTower Advisors first reported a position in BIB in Q1 2014 and held it in 5 quarters. The position peaked at $548K in Q2 2014. 27 funds tracked by Wall St. Rank hold BIB as of Q2 2015.

  • HighTower Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2015 after selling out during the quarter.
  • HighTower Advisors sold 6,108 ProShares Ultra NASDAQ Biotechnology shares in Q2 2015, an estimated $484K.
  • HighTower Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2014 and held it in 5 quarters.
  • HighTower Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $548K in Q2 2014.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2015.

Based on HighTower Advisors's 13F filing for Q2 2015, filed 11 Aug 2015.